1843 - 2023

London Health Sciences Centre – A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (*Only Arm 6 open at Sunnybrook)

It seems we can’t find what you’re looking for. Perhaps searching can help.